

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5105598

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARK IAN KEMP	06/26/2018
MARTIN LEE STOCKLEY	06/22/2018
ANDREW MADIN	06/18/2018
RECEIVING PARTY DATA	
Name:	MISSION THERAPEUTICS LIMITED
Street Address:	MONETA (BUILDING 280)
Internal Address:	BABRAHAM RESEARCH CAMPUS
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB22 3AT
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15781615
CORRESPONDENCE DATA	
Fax Number:	(973)639-8399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	973-596-4500
Email:	IPdocket@gibbonslaw.com
Correspondent Name:	GIBBONS P.C.
Address Line 1:	ONE GATEWAY CENTER
Address Line 4:	NEWARK, NEW JERSEY 07102
ATTORNEY DOCKET NUMBER:	114683-98141 (P015-US1)
NAME OF SUBMITTER:	SAMUEL H. MEGERDITCHIAN
SIGNATURE:	/Samuel H. Megerditchian/
DATE SIGNED:	08/23/2018
Total Attachments: 4	
source=Assignment-15781615#page1.tif	
source=Assignment-15781615#page2.tif	
source=Assignment-15781615#page3.tif	

ASSIGNMENT

WHEREAS, We, Mark Ian KEMP, c/o Mission Therapeutics Limited, Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, Great Britain;

Martin Lee STOCKLEY, c/o Mission Therapeutics Limited, Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, Great Britain; and

Andrew MADIN, c/o Mission Therapeutics Limited, Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, Great Britain;

(Assignors), have invented certain new and useful improvements which are described and claimed in United States Patent Application No. 15/781,615 filed June 5, 2018, entitled

NOVEL COMPOUNDS

WHEREAS, MISSION THERAPEUTICS LIMITED (Assignee), having its principal place of business at Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, is desirous of acquiring the entire interest in and to said invention, said applications and all patents to be obtained therefrom.


NOW, THEREFORE, for and in consideration of valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, I have sold, assigned, and set over, and by these presents do hereby sell, assign and set over unto the said MISSION THERAPEUTICS LIMITED (Assignee), and said Assignee's legal representatives, successors, the entire right, title and interest, for the whole world, in and to said invention and said applications, as well as any subsequent application which claims priority based upon the filing date of any of said applications identified and the patents, both domestic and foreign, that may or shall result therefrom including the right to claim in respect of any subsequent United States and foreign patent applications and patents, the priority date of any of said applications under any United States statute and international convention or treaty; and I do hereby authorize and request the issuance of said patents, domestic and foreign, conformably to the terms of this Agreement.

UPON SAID CONSIDERATION, I do hereby covenant and agree with said Assignee that we will not execute any writing or do any act whatsoever conflicting with these presents, and that will at any time upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings and so such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining provisional, original, continuation, continuation-in-part, divisional, reissued, re-examined or extended patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such


applications or patents, including but not limited to, giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of all parties hereto.

The undersigned declares under penalty of perjury under the laws of the United States of America that he has signed this document as his own free act and that all of the foregoing is true and correct.

26/6/18
Date


Mark Ian KEMP, Assignor

22/06/2018
Date


Martin Lee STOCKLEY, Assignor

Date

Andrew MADIN, Assignor

ASSIGNMENT

WHEREAS, We, **Mark Ian KEMP**, c/o Mission Therapeutics Limited, Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, Great Britain;

Martin Lee STOCKLEY, c/o Mission Therapeutics Limited, Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, Great Britain; and

Andrew MADIN, c/o Mission Therapeutics Limited, Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, Great Britain;

(Assignors), have invented certain new and useful improvements which are described and claimed in United States Patent Application No. 15/781,615 filed June 5, 2018, entitled

NOVEL COMPOUNDS

WHEREAS, **MISSION THERAPEUTICS LIMITED** (Assignee), having its principal place of business at Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, is desirous of acquiring the entire interest in and to said invention, said applications and all patents to be obtained therefrom.

NOW, THEREFORE, for and in consideration of valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, I have sold, assigned, and set over, and by these presents do hereby sell, assign and set over unto the said **MISSION THERAPEUTICS LIMITED** (Assignee), and said Assignee's legal representatives, successors, the entire right, title and interest, for the whole world, in and to said invention and said applications, as well as any subsequent application which claims priority based upon the filing date of any of said applications identified and the patents, both domestic and foreign, that may or shall result therefrom including the right to claim in respect of any subsequent United States and foreign patent applications and patents, the priority date of any of said applications under any United States statute and international convention or treaty; and I do hereby authorize and request the issuance of said patents, domestic and foreign, conformably to the terms of this Agreement.

UPON SAID CONSIDERATION, I do hereby covenant and agree with said Assignee that we will not execute any writing or do any act whatsoever conflicting with these presents, and that will at any time upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional assignments and other writings and so such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining provisional, original, continuation, continuation-in-part, divisional, reissued, re-examined or extended patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such

applications or patents, including but not limited to, giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of all parties hereto.

The undersigned declares under penalty of perjury under the laws of the United States of America that he has signed this document as his own free act and that all of the foregoing is true and correct.

Date

Mark Ian KEMP, Assignor

Date

Martin Lee STOCKLEY, Assignor

18 June 2018
Date

Andrew Madin
Andrew MADIN, Assignor